Free Biopharma Daily Stock Updates - 06/16/21

$XBI +$134.0 +0.0%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$MRNA -1.9% U.S. Government Purchases Additional 200 Million Doses of Moderna’s COVID-19 Vaccine source

$NVAX -5.8% Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously source

Pipeline Updates

$AMPE -3.2% Ampio Pharmaceuticals Receives Approval to Expand Enrollment of its AP-019 Phase II Study to India source

$UTHR +3.0% United Therapeutics Announces FDA Acceptance of Tyvaso DPI™ New Drug Application For Priority Review source

$MNKD +5.6% MannKind and United Therapeutics Achieve a Major Milestone in the Development of Tyvaso DPI™ With New Drug Application Acceptance From the FDA source

$SWTX +-0.1% SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma source

$EPZM +0.5% Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients source

$BCRX +3.0% BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Application by the Israeli Ministry of Health source

$ALT +16.5% Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers source

$TRVN -1.0% Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder source

$QURE -0.01% uniQure Announces Enrollment of First Two Patients in Second Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease source

$PSTV +1.5% Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT™ Glioblastoma Trial source

$PRTK -12.1% Paratek Pharmaceuticals Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc) with NUZYRA® (omadacycline) source

$DRNA -0.50% Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3 source

$FGEN +2.0% Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform source

$APRE +11.0% Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint source

$ALT +16.5% Altimmune Announces Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers source

$BPMC +1.3% FDA Approves Blueprint Medicines' AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis source

$TARS +1.0% Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease source

$AVXL +21.5% On 6/14 Anavex Life Sciences Reports New Publication in Medical Journal Elucidating the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) related to the Treatment of Alzheimer’s Disease. source

$FUSN -14.0% On 6/14 Fusion Pharmaceuticals Announces Preliminary Safety and Dosimetry Results from its Single-Dose Portion of the Phase 1 Study of FPI-1434 source

$OPT +20.4% Opthea surges 41% as potential beneficiary of Clearside wet AMD data. source

Financial Updates

$AVIR -0.50% Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with Roche source

$SAVA +11.3% On 6/14 Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors. source

$YMTX -12.1% On 6/14 Yumanity Therapeutics Appoints Devin W. Smith as General Counsel. Source

$ORPH +61.3% Major shareholder announcement. as of June 11, 2021, Sunstone Life Science Ventures Fund II K/S holds less than 5% of the Company’s share capital and that Sunstone Life Science Ventures A/S controls less than 5% of the voting rights in the Company. Source

---

Posted by JM/MV